830 related articles for article (PubMed ID: 20213096)
1. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
2. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
4. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
[TBL] [Abstract][Full Text] [Related]
5. Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-beta expression driven by hTERT promoter.
He LF; Wang YG; Xiao T; Zhang KJ; Li GC; Gu JF; Chu L; Tang WH; Tan WS; Liu XY
Cancer Lett; 2009 Dec; 286(2):196-205. PubMed ID: 19564073
[TBL] [Abstract][Full Text] [Related]
6. [Effects of human telomerase reverse transcriptase promoter and survivin promoter in targeted tumor gene therapy].
Zhang Y; Ma H; Liu SL; Liu YX; Zheng DX
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(7):475-9. PubMed ID: 18642790
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W
Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258
[TBL] [Abstract][Full Text] [Related]
8. [Specific antitumor effect of adeno-associated virus vector carrying TRAIL gene under the control of hTERT promoter].
Qi R; Cai Y; Li BH; Lin ZX; Gu JF
Ai Zheng; 2008 Oct; 27(10):1026-33. PubMed ID: 18851780
[TBL] [Abstract][Full Text] [Related]
9. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S
Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092
[TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase interference synergistically promotes tumor necrosis factor‑related apoptosis‑inducing ligand‑induced oral squamous cell carcinoma apoptosis and suppresses proliferation in vitro and in vivo.
Zhao X; Zhang C; Le Z; Zeng S; Pan C; Shi J; Wang J; Zhao X
Int J Mol Med; 2018 Sep; 42(3):1283-1294. PubMed ID: 29901096
[TBL] [Abstract][Full Text] [Related]
11. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
Ma H; Liu Y; Liu S; Xu R; Zheng D
Hepatology; 2005 Dec; 42(6):1355-63. PubMed ID: 16317690
[TBL] [Abstract][Full Text] [Related]
12. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
13. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter].
Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B
Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959
[TBL] [Abstract][Full Text] [Related]
14. RNA interference-mediated hTERT inhibition enhances TRAIL-induced apoptosis in resistant hepatocellular carcinoma cells.
Zhang RG; Zhao JJ; Yang LQ; Yang SM; Wang RQ; Chen WS; Peng GY; Fang DC
Oncol Rep; 2010 Apr; 23(4):1013-9. PubMed ID: 20204286
[TBL] [Abstract][Full Text] [Related]
15. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
16. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.
Wang WB; Zhou YL; Heng DF; Miao CH; Cao YL
Breast Cancer Res Treat; 2008 Jul; 110(2):283-95. PubMed ID: 17899369
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
18. Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement.
Won YS; Jeong JS; Kim SJ; Ju MH; Lee SW
Cancer Lett; 2015 Jan; 356(2 Pt B):918-28. PubMed ID: 25444904
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of a novel adeno-associated virus vector targeting to telomerase activity in tumor cells.
Wang YG; Wang JH; Zhang YH; Gu Q; Liu XY
Acta Biochim Biophys Sin (Shanghai); 2004 Jul; 36(7):492-500. PubMed ID: 15248024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
